Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
暂无分享,去创建一个
Winand N M Dinjens | Jean-Yves Delattre | Denis Lacombe | Wolfgang Grisold | Mathilde C M Kouwenhoven | Johan M Kros | K. Hoang-Xuan | M. J. van den Bent | M. Taphoorn | A. Brandes | T. Gorlia | A. Allgeier | D. Lacombe | W. Dinjens | P. French | J. Kros | J. Delattre | C. Vecht | C. Tijssen | M. Kouwenhoven | Pim J French | Martin J van den Bent | Thierry Gorlia | W. Grisold | Marc Frenay | Charles J Vecht | Khê Hoang-Xuan | M. Frénay | Martin J B Taphoorn | Alba A Brandes | Hans J J A Bernsen | Cees C Tijssen | Anouk Allgeier | László Sipos | Roelien H Enting | L. Sipos | R. Enting | H. Bernsen
[1] D K Pearl,et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.
[2] Denis Lacombe,et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Berger,et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.
[4] K. Hoang-Xuan,et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951 , 2010, Journal of Neuro-Oncology.
[5] P. Kleihues,et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.
[6] Caterina Giannini,et al. Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations With Outcome , 2007, Journal of neuropathology and experimental neurology.
[7] Pieter Wesseling,et al. IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group , 2010, Clinical Cancer Research.
[8] M. J. van den Bent,et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. , 2006, European journal of cancer.
[9] P. Burger,et al. What is an Oligodendroglioma? , 2002, Brain pathology.
[10] D. Louis,et al. Survey of treatment recommendations for anaplastic oligodendroglioma. , 2007, Neuro-oncology.
[11] P. Rothwell,et al. External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.
[12] M. J. van den Bent,et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] K. Aldape,et al. Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 , 2008, Brain pathology.
[14] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[15] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[16] Walter Curran,et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[18] O. G. Dodge,et al. Histological Typing of tumours of the Central Nervous System , 1981, British Journal of Cancer.
[19] L. Douw,et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up , 2009, The Lancet Neurology.
[20] R. Mirimanoff,et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. , 2009, Neuro-oncology.
[21] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] T. Cascino,et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Twijnstra,et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy , 1998, Neurology.
[24] K. Hopkins,et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Jean-Yves Delattre,et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. , 2011, Neuro-oncology.
[26] R. Wilson,et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.
[27] D. Louis,et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.
[28] M. J. van den Bent,et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. J. van den Bent,et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features , 2003, Cancer.
[30] Pieter Wesseling,et al. A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951 , 2011, Clinical Cancer Research.
[31] Martin J. Bent,et al. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective , 2010, Acta Neuropathologica.
[32] Andrey Korshunov,et al. Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.
[33] E. Shaw,et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] A. Brandes,et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy , 2004, Cancer.
[35] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[36] A. Viale,et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.
[37] G. Reifenberger,et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.